- Nineteen prisoners use cutlery to break out of cells at Winchester prison
- France wants progress in Ukraine before Russia returns to G7
- Italy president begins talks to seek way out of government crisis
- Italian PM expected to resign as political chaos deepens
- Russia says US cruise missile test ‘regrettable’
- Kremlin - No date set for Normandy talks on Ukraine despite Macron meeting
- Egypt court hands out 6 death sentences on terror charges
- Putin says Russian nuclear explosion poses no threat
- Russian panel eyes alleged foreign interference in protests
- Gran Canaria wildfire triggers evacuation of thousands of people
- PM Johnson calls on Germany and France to compromise on Brexit
- Sudan's ex-president Bashir arrives at corruption trial
TEHRAN, Feb 06 -Britain’s AstraZeneca said a potential medicine to prevent respiratory syncytial virus (RSV) in babies and infants had been granted special status by U.S. and European regulators, designed to speed up the development of novel and better drugs.
TEHRAN, Young Journalists Club (YJC) -The “Breakthrough Therapy” and “Prime” designations in the United States and Europe respectively were based on early results from Phase IIb trials of MEDI8897, AstraZeneca said.
The drug is being developed for use in a broader infant population than the standard of care for RSV prevention, Synagis, which needs monthly injections and is therefore only approved in Europe for high-risk infants.
MEDI8897, which is being developed in partnership with Sanofi Pasteur, only requires one dose during a typical five month RSV season, AstraZeneca said.
RSV is the most common cause of lower respiratory tract infection in infants and children worldwide, and 90 percent of children are infected with RSV in the first two years of life.
Source: Reuters
Your Comment